Last update 15 Feb 2025

Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
KITE-363
Target
CD19 x CD20
Action-
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Immunologic cytotoxicity
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Large B-cell lymphoma
Inactive Indication-
Originator Organization
Kite Pharma, Inc.Kite Pharma, Inc.
Active Organization
Kite Pharma, Inc.Kite Pharma, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
NCT05041309
/ Enrolling by invitationPhase 2
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
NCT04989803
/ RecruitingPhase 1
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
100 Clinical Results associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data
100 Translational Medicine associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data
100 Patents (Medical) associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data
100 Deals associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Large B-cell lymphomaPhase 1
United States
Kite Pharma, Inc.Kite Pharma, Inc.
27 Oct 2021
Large B-cell lymphomaPhase 1
Australia
Kite Pharma, Inc.Kite Pharma, Inc.
27 Oct 2021
Large B-cell lymphomaPhase 1
Germany
Kite Pharma, Inc.Kite Pharma, Inc.
27 Oct 2021
Large B-cell lymphomaPhase 1
Netherlands
Kite Pharma, Inc.Kite Pharma, Inc.
27 Oct 2021
Large B-cell lymphomaPhase 1
United Kingdom
Kite Pharma, Inc.Kite Pharma, Inc.
27 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free